Literature DB >> 17952872

Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays.

Mary Winters1, Bhavana Dabir, Minshu Yu, Elise C Kohn.   

Abstract

Application of novel technology to clinical samples requires optimization of procedures. Reverse phase protein lysate arrays use femtomolar quantities of tissue lysate from clinical samples with which to profile biochemical events happening in the tumor. We analyzed the effects of different tissue solubilization buffers on frozen ovarian tumor samples in order to identify the system with the best signal intensity dynamic range, reproducibility, tissue solubility, and signal consistency. A modified RIPA-like buffer supplemented with DTT and SDS was deemed optimal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952872     DOI: 10.1002/pmic.200700484

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  11 in total

1.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.

Authors:  Geoffrey Kim; Ben Davidson; Ryan Henning; Junbai Wang; Minshu Yu; Christina Annunziata; Thea Hetland; Elise C Kohn
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 2.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

Review 3.  Proteomics and biomarkers in clinical trials for drug development.

Authors:  Jung-min Lee; Jasmine J Han; Gary Altwerger; Elise C Kohn
Journal:  J Proteomics       Date:  2011-05-04       Impact factor: 4.044

4.  Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Authors:  Jung-Min Lee; John L Hays; Christina M Annunziata; Anne M Noonan; Lori Minasian; Jo Anne Zujewski; Minshu Yu; Nicolas Gordon; Jiuping Ji; Tristan M Sissung; William D Figg; Nilofer Azad; Bradford J Wood; James Doroshow; Elise C Kohn
Journal:  J Natl Cancer Inst       Date:  2014-05-19       Impact factor: 13.506

5.  Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations.

Authors:  Alessandra Silvestri; Valerie Calvert; Claudio Belluco; Michael Lipsky; Ruggero De Maria; Jianghong Deng; Alfonso Colombatti; Francesco De Marchi; Donato Nitti; Enzo Mammano; Lance Liotta; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Clin Exp Metastasis       Date:  2012-09-29       Impact factor: 5.150

Review 6.  Proteomics as a guiding tool for more effective personalized therapy.

Authors:  J-M Lee; E C Kohn
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

Review 7.  Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.

Authors:  Allison Marrero; Scott Lawrence; Deborah Wilsker; Andrea Regier Voth; Robert J Kinders
Journal:  Semin Oncol       Date:  2016-06-14       Impact factor: 4.929

Review 8.  Proteomic profiling in ovarian cancer.

Authors:  Geoffrey Kim; Lucas Minig; Elise C Kohn
Journal:  Int J Gynecol Cancer       Date:  2009-12       Impact factor: 3.437

9.  Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.

Authors:  Nilofer Azad; Minshu Yu; Ben Davidson; Peter Choyke; Clara C Chen; Bradford J Wood; Aradhana Venkatesan; Ryan Henning; Kathy Calvo; Lori Minasian; Daniel C Edelman; Paul Meltzer; Seth M Steinberg; Christina M Annunziata; Elise C Kohn
Journal:  Mol Cell Proteomics       Date:  2013-02-28       Impact factor: 5.911

10.  Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

Authors:  Christina M Annunziata; Amanda J Walker; Lori Minasian; Minshu Yu; Herbert Kotz; Bradford J Wood; Katherine Calvo; Peter Choyke; Daniel Kimm; Seth M Steinberg; Elise C Kohn
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.